scholarly journals Meal Skipping among Patients with Type 2 Diabetes Mellitus (T2DM) and Its Associations with Glycaemic Control, Eating Out of Home and Binge Eating

2020 ◽  
Vol 15 (2) ◽  
pp. 246-261
Author(s):  
Hizlinda Tohid. ◽  

Meal skipping is a common way to restrict diet, but its practice by patients with type 2 diabetes mellitus (T2DM) remains undetermined due to the scarcity of the research. The main aim of this study was to assess how common patients with T2DM skipped meals. Its associations with sociodemographic and clinical characteristics, HbA1c, eating out of home and binge eating were examined too. This cross-sectional study was conducted in 2015 among 203 patients at a public healthcare clinic in Kuala Lumpur. A self-administered questionnaire including the Malay-version Binge Eating Scale was used. The proportions of participants who frequently skipped meals and ate out of home were 41.4% and 61.6%, respectively. Only 2% of them had binge eating disorder. Multiple logistic regression showed only Chinese was significantly associated with frequent meal skipping compared to Malay (adjusted odds ratio: 0.36; 95% confidence interval: 0.16-0.77; p value= 0.009) after controlling for age, employment status, educational status, HbA1c, presence of complication, type of treatment, eating out of home and binge eating. In conclusion, meal skipping was a frequently practised eating behaviour. Eating out of home was common too, but binge eating was rare. Meal skipping was not influenced by both eating practices and it had insignificant associations with glycaemic control. Cultural and religious factors may play an important role in defining their eating practice. Further studies are needed to assess the safety and acceptability of this practice, but clinically, its effects must be individually examined to prevent unwanted consequences on their health.

2021 ◽  
Author(s):  
Martin R Cowie

Tweetable abstract Sodium–glucose cotransporter-2 inhibitors not only improve glycaemic control in Type 2 diabetes mellitus but convincingly improve outcome for everyone with HFrEF and albuminuric kidney disease. Trials then license – now all we need is implementation


2021 ◽  
Author(s):  
Elisabeth Höld ◽  
Johanna Grüblbauer ◽  
Martin Wiesholzer ◽  
Daniela Wewerka-Kreimel ◽  
Stefan Stieger ◽  
...  

Abstract Background: the context and purpose of the studyDiabetes mellitus is one of the four priority non-communicable diseases worldwide. It can lead to serious long-term complications and produces significant costs. Due to the chronicle character of the disease, it requires continuous medical treatment and good therapy adherence of those suffering. Therefore, diabetes self-management education (DSME) (and support DSMES) plays a significant role to increase patient’s self-management capacity and improve diabetes therapy. Research indicates that these outcomes might be difficult to maintain. Consequently, effective strategies to preserve the positive effects of DSMES are needed. Preliminary results show that peer support, which means support from a person who has experiential knowledge of a specific behaviour or stressor and similar characteristics as the target population, is associated with better outcomes in terms of HbA1c, cardiovascular disease risk factors or self-efficacy at lower cost compared to standard therapy. Peer-supported instant messaging services (IMS) approaches have significant potential for diabetes management because support can be provided easily and prompt, is inexpensive, and needs less effort to attend compared to standard therapy. The major objective of the study is to analyse the impact of a peer-supported IMS intervention in addition to a standard diabetes therapy on the glycaemic control of type 2 diabetic patients. Methods: how the study will be performedA total of 205 participants with type 2 diabetes mellitus will be included and randomly assigned to intervention or control group. Both groups will receive standard therapy, but the intervention group will participate in the peer-supported IMS intervention, additionally. The duration of the intervention will last for seven months, followed by a follow-up of seven months. Biochemical, behavioural and psychosocial parameters will be measured before, in the middle, and after the intervention as well as after the follow-up.Discussion: a brief summary and potential implicationsDiabetes mellitus type 2 and other non-communicable diseases put healthcare systems worldwide to the test. Peer-supported IMS interventions in addition to standard therapy might be part of new and cost-effective approaches to support patients independent from time and place.Trial registration: If your article reports the results of a health care intervention on human participants, it must be registered in an appropriate registry and the registration number and date of registration should be in stated in this section. If it was not registered prospectively (before enrollment of the first participant), you should include the words 'retrospectively registered'. See our editorial policies for more information on trial registration.ClinicalTrials.gov Identifier: NCT04797429Date of registration: 15 March 2021


Sign in / Sign up

Export Citation Format

Share Document